- These tumors account for approximately 1% of papillary thyroid cancers and are typically associated with a V600E mutation in the BRAF gene
- Most patients have evidence of disease after initial therapy, and the five-year mortality higher than in patients with classical papillary thyroid cancers
- This variant is characterized by:
- Elongated tumor cells (height twice the width) lining the papillary structures, involving at least 50% of the tumor
- Proper identification of this variant is critical:
- As it is associated with a more aggressive phenotype
- They are characterized by:
- Tumor cells with eosinophilic cytoplasm that are twice as tall as they are wide
- TCV is more likely to present with:
- Larger tumors
- Lymph node
- Distant metastases
- Extracapsular extension
- Mortality is significantly higher than for classic PTC:
- Although it is not known why these tumors are more aggressive, it could be related to their molecular profile:
- As many as 80% may express BRAF
- In addition, these tumors are frequently PET positive and radioiodine refractory
#Arrangoiz #ThyroidSurgeon #CancerSurgeon #SurgicalOncologist #HeadandNeckSurgeon #EndocrineSurgery #ThyroidCancer #TallCellVariantofPapillaryThyroidCancer #Miami #Mexico #MountSinaiMedicalCenter
Like this:
Like Loading...
Related
Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO
My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
View all posts by Rodrigo Arrangoiz MS, MD, FACS, FSSO
Rodrigo Arrangoiz MS, MD, FACS, FSSO 